Trending Now
SPY ready to draw blood on Wall Street
Looks like the bull rally on SPY is finally going to come to an end today. We saw a pullback this weekend...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Selecta Biosciences Inc. (NASDAQ:SELB) Announces Q3 2020 And Offers Business Updates...
Selecta Biosciences Inc. (NASDAQ:SELB) has announced its Q3 2020 financial results and offered its corporate updates.
COMPARE Results Show potential of ImmTOR platform
The company’s...
MAKE IT MODERN
LATEST REVIEWS
Alkermes plc. (NASDAQ: ALKS) To Present A Poster About Nemvaleukin Alfa...
Alkermes plc. (NASDAQ: ALKS) has announced intentions to present a poster in connection to nemvaleukin alfa, its novel, experimental, engineering interleukin-2 variant immunotherapy, at...
MAKE IT MODERN
PERFORMANCE TRAINING
Trevena Inc (NASDAQ:TRVN) Collaborates with Imperial College London to Conduct a Proof-of-Concept Study for...
The presence of COVID-19 continues to be one of the trending topics across the world. However, efforts to bring forth a potential vaccine are...
Allakos Inc (NASDAQ:ALLK) Publishes Its Phase 2 Study of Lirentelimab In The New England...
Allakos Inc (NASDAQ:ALLK) recently announced that the findings from its phase 2 study evaluating lirentelimab (AK002) were published in the latest edition of the...
Brickell Biotech Inc. (NASDAQ:BBI) To Launch Sofpironium bromide gel, 5% In Japan For Primary...
Brickell Biotech Inc. (NASDAQ:BBI) has announced that Kaken Pharmaceutical Co Ltd, its Japanese development partner, will launch ECCLOCK® (sofpironium bromide gel) 5%...
Otonomy Inc. (NASDAQ:OTIC) Release Positive Phase 1/2 OTO-313 Clinical Study Results In Tinnitus Patients
Otonomy Inc. (NASDAQ:OTIC) announced positive phase 1/2 top-line results in the OTO-313 study in patients having moderately severe persistent tinnitus. The company also provided...
This Small Cap Could be the Lotto Ticket in the Emerging Carbon Capture Story...
The coming decade will be defined by several major macro themes for investors. Perhaps foremost among them will be derivative themes related...
MAKE IT MODERN
